Trial
NCT00616122
Sunitinib, Cyclophosphamide, and Methotrexate in Treating Patients With Metastatic Breast Cancer
Phase ITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
University of California, San Francisco
Collaborators
National Cancer Institute (NCI)
Condition
Breast Cancer
Intervention
cyclophosphamide
Why stopped
Risk to benefit ratio not acceptable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-01-13